|
|
(Transportation-News.com, July 14, 2018 ) Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.
Publisher's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
For more information about this report @ http://www.reportsweb.com/thyroid-cancer-pipeline-review-h1-2017
The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 29, 21, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 5 molecules, respectively.
Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)
Request a sample copy @ http://www.reportsweb.com/inquiry&RW0001709419/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
AbbVie Inc
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Biovista Inc
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Celgene Corp
Celldex Therapeutics Inc
Cytori Therapeutics Inc
Daiichi Sankyo Company Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Ensol Biosciences Inc
F. Hoffmann-La Roche Ltd
Genelux Corp
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc
Hutchison MediPharma Ltd
Ignyta Inc
Immune Pharmaceuticals Inc
Immunomedics Inc
Johnson & Johnson
Loxo Oncology Inc
MacroGenics Inc
MaxiVAX SA
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Nerviano Medical Sciences Srl
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Plexxikon Inc
Rodos BioTarget GmbH
Savoy Pharmaceuticals Inc
Synactix Pharmaceuticals Inc
Tarveda Therapeutics Inc
Vaccinex Inc
Vascular Biogenics Ltd
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
